Back to News

Ophthalmology Futures Forums – Euro Retina Virtual Forum, September 8, 2021

Ophthalmology Futures Forums are clinician-driven innovation meetings focusing on new technology, entrepreneurial ventures, market access, and other aspects of commercialisation in the ophthalmic healthcare sector. They cover all aspects of global innovation in ophthalmic devices, diagnostics, and pharmaceuticals by connecting scientists, physicians, regulators, reimbursement specialists, corporate leaders, venture capitalists, and other investors who support the advancement of eye care. 2021 Euro Retina Forums will be going completely virtual on September 8, 2021. GenSight Biologics is a Bronze Sponsor and Dr Magali Taiel, Chief Medical Officer, will participate to a panel and will present the company and the latest news on our lead product candidate LUMEVOQ® (GS010; lenadogene nolparvovec) as detailed below: Panel:  Gene Therapy and Gene Editing for Rare and Common Retinal Diseases
  • Time : 14:30 – 15:00 CEST
Company Presentations 1
  • Time: 15:00 – 16:00 CEST
Back to News

A New Chapter

Founded in 2012 to realize the potential of gene therapy, GenSight Biologics has grown into a clinical-stage company advancing multiple programs. In 2024, under a new management team, the company entered a new phase and is now accelerating its clinical and regulatory activities.

Explore investors’ hub

GenSight Biologics S.A.
74 rue du Faubourg Saint-Antoine
75012 Paris
France